

Vivianne Presta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3542508/vivianne-presta-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

336
papers

13,465
citations

39
h-index

111
g-index

417
ext. papers

17,128
ext. citations

4.4
avg, IF

6.2
L-index

#	Paper	IF	Citations
336	Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity.. <i>European Heart Journal</i> , 2022 ,	9.5	1
335	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention.. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022 , 29, 91	2.9	1
334	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. <i>European Heart Journal</i> , 2022 , 43, 448-449	9.5	1
333	Implantable recorders and systematic atrial fibrillation detection do not outperform standard of care in stroke prevention in the LOOP study.. <i>European Heart Journal</i> , 2022 , 43, 261-262	9.5	0
332	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension.. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022 , 1	2.9	0
331	VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?. <i>European Heart Journal</i> , 2022 , 43, 181-182	9.5	
330	Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice.. <i>Internal and Emergency Medicine</i> , 2022 , 17, 645	3.7	0
329	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction.. <i>European Heart Journal</i> , 2022 , 43, 559-560	9.5	2
328	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey.. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022 ,	2.9	1
327	New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. <i>Medical Sciences (Basel, Switzerland)</i> , 2022 , 10, 27	3.3	0
326	100% Fruit juice intake and cardiovascular risk: a systematic review and meta-analysis of prospective and randomised controlled studies. <i>European Journal of Nutrition</i> , 2021 , 60, 2449-2467	5.2	10
325	Antihypertensive drugs and the risks of cancer: More fakes than facts. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 1323-1326	3.9	3
324	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications.. <i>Frontiers in Medicine</i> , 2021 , 8, 798958	4.9	10
323	Relationship Between Cardiorespiratory Fitness, Baseline Blood Pressure and Hypertensive Response to Exercise in the Ferrari Corporate Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 29, 81	2.9	2
322	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 29, 1	2.9	6
321	Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?. <i>European Heart Journal</i> , 2021 , 42, 4885-4886	9.5	0
320	An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation. <i>Cell Death and Disease</i> , 2021 , 12, 919	9.8	5

319	Another STEP towards tighter control of blood pressure in the elderly. <i>European Heart Journal</i> , 2021 , 42, 4715-4716	9.5	
318	Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. <i>Journal of Hypertension</i> , 2021 , 39, 169-180	1.9	0
317	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. <i>European Heart Journal</i> , 2021 , 42, 14-15	9.5	1
316	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. <i>European Heart Journal</i> , 2021 , 42, 370-371	9.5	3
315	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021 , 39, 62-69	1.9	17
314	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021 , 39, 333-340	1.9	17
313	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 376-380	1.9	11
312	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. <i>Cardiovascular Research</i> , 2021 , 117, 1992-1994	9.9	1
311	Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	2
310	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 28, 255-262	2.9	1
309	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <i>European Heart Journal</i> , 2021 , 42, 1458-1459	9.5	2
308	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2021 , 1	4.8	15
307	Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. <i>International Journal of Cardiology</i> , 2021 , 329, 23-27	3.2	3
306	Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 661-666	5.1	2
305	Hypertension, a Moving Target in COVID-19: Current Views and Perspectives. <i>Circulation Research</i> , 2021 , 128, 1062-1079	15.7	22
304	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 28, 325-326	2.9	
303	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 633878	5.4	3
302	Vulnerable non-culprit coronary plaques: are they worth treating?. <i>European Heart Journal</i> , 2021 , 42, 2233-2234	9.5	

301	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2021 , 23, B77-B81	1.5	1
300	Role of induced pluripotent stem cells in diagnostic cardiology. <i>World Journal of Stem Cells</i> , 2021 , 13, 331-341	5.6	0
299	Glycaemic index: an emergent global silent killer for the heart. <i>European Heart Journal</i> , 2021 , 42, 2727-2738	9.5	0
298	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. <i>European Heart Journal</i> , 2021 , 42, 2329-2330	9.5	0
297	Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials. <i>Journal of Interventional Cardiology</i> , 2021 , 2021, 9917407	1.8	1
296	A SPRINT towards tighter control of blood pressure in hypertension. <i>European Heart Journal</i> , 2021 , 42, 3042-3043	9.5	2
295	Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalities in cardiovascular outcomes in US and UK adults: a call for action for social cardiology. <i>European Heart Journal</i> , 2021 , 42, 2420-2421	9.5	0
294	Reply to the letter "Takotsubo syndrome: Any more covariates of its recurrence?". <i>International Journal of Cardiology</i> , 2021 , 333, 54	3.2	
293	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. <i>European Heart Journal</i> , 2021 , 42, 2814-2815	9.5	3
292	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 28, 12-18	2.7	8
291	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021 , 322, 245-249	3.2	2
290	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021 , 327, 138-145	3.2	12
289	FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease.. <i>European Heart Journal</i> , 2021 , 42, 4789-4790	9.5	2
288	The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 4621-4623	9.5	3
287	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 28, 5-11	2.9	9
286	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	2
285	Real-life appraisal on blood pressure targets achievement in adult outpatients at high cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 472-480	4.5	0
284	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. <i>European Heart Journal</i> , 2021 , 42, 1061-1062	9.5	1

283	Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24 h ambulatory blood pressure monitoring database. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	1
282	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1073-1082	6.1	8
281	The UrgeRe (Urgenze Ipertensive: Un Progetto Educazionale Fondato Sulla Vita Reale, Hypertensive Urgencies: A Project in the Real World) Project. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 28, 151-157	2.9	0
280	Cryoblation as first-line treatment of new-onset atrial fibrillation?. <i>European Heart Journal</i> , 2021 , 42, 1543-1544	9.5	0
279	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. <i>Frontiers in Physiology</i> , 2021 , 12, 643721	4.6	4
278	Worsening of risk factor control in US diabetic patients: a call to action. <i>European Heart Journal</i> , 2021 , 42, 3120-3121	9.5	
277	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 3902-3903	9.5	
276	A Once-and-Done Approach to the Lifelong Reduction of Elevated Cholesterol. <i>European Heart Journal</i> , 2021 , 42, 3820-3821	9.5	1
275	Exploring RNA biomarkers in patients with acute myocarditis. <i>European Heart Journal</i> , 2021 , 42, 3425-3436	9.5	
274	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 703418	5.4	0
273	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , 2021 , 12, 652163	4.6	6
272	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4518-4519	9.5	0
271	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	3
270	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , 2021 ,	1.6	1
269	An inflammatory ageing clock to detect cardiovascular and other age-related diseases: a new approach to preventive medicine. <i>European Heart Journal</i> , 2021 , 42, 4296-4297	9.5	0
268	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 832-839	1.9	3
267	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 713652	5.4	1
266	Trehalose, a natural disaccharide, reduces stroke occurrence in the stroke-prone spontaneously hypertensive rat. <i>Pharmacological Research</i> , 2021 , 173, 105875	10.2	2

265	Long-term management of Takotsubo syndrome: a not-so-benign condition. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 597-611	3.9	0
264	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. <i>Cardiovascular Research</i> , 2020 , 116, 429-437	9.9	13
263	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 195-201	2.9	0
262	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
261	Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
260	Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy. <i>European Journal of Internal Medicine</i> , 2020 , 78, 95-100	3.9	6
259	Prognostic implications of nonsustained ventricular tachycardia morphology in high-risk patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2093-2098	2.7	0
258	A systematic review on focal takotsubo syndrome: a not-so-small matter. <i>Heart Failure Reviews</i> , 2020 , 1	5	7
257	Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. <i>Hypertension</i> , 2020 , 76, 366-372	8.5	216
256	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020 , 316, 172-179	3.2	8
255	Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 109-117	2.9	7
254	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 907-914	4.4	17
253	Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions - Comparison of uremic, hypertensive and hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020 , 306, 102-108	3.2	16
252	Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high-output heart failure due to high-flow forearm arteriovenous fistula. <i>Journal of Vascular Access</i> , 2020 , 21, 753-759	1.8	1
251	The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly. <i>European Journal of Heart Failure</i> , 2020 , 22, 1740-1741	12.3	5
250	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 105-108	2.9	32
249	Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?. <i>European Cardiology Review</i> , 2020 , 15, e21	3.9	3
248	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020 , 26, 932-943	3.3	2

247	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020 , 38, 1005-1015	1.9	4
246	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 51-59 ^{2,9}	2.9	12
245	Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. <i>Internal and Emergency Medicine</i> , 2020 , 15, 373-379	3.7	3
244	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. <i>Hypertension</i> , 2020 , 75, 302-308	8.5	76
243	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020 , 21, 1405-1411	4.1	2
242	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. <i>Angiology</i> , 2020 , 71, 217-225	2.1	2
241	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. <i>Journal of Hypertension</i> , 2020 , 38, 412-419	1.9	34
240	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. <i>Hypertension</i> , 2020 , 76, 1753-1761	8.5	7
239	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. <i>PLoS ONE</i> , 2020 , 15, e0237297	3.7	24
238	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1467-1476 ^{2,7,28}	3.7	28
237	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2020 , 22, H70-H73	1.5	1
236	Blood Pressure Target Achievement Under Monotherapy: A Real-Life Appraisal. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 587-596	2.9	6
235	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. <i>European Heart Journal Supplements</i> , 2020 , 22, L166-L169	1.5	1
234	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
233	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. <i>International Journal of Cardiology</i> , 2020 , 321, 150-154	3.2	10
232	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 373-377	2.9	10
231	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. <i>European Heart Journal</i> , 2020 , 41, 3986-3987	9.5	
230	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. <i>Scientific Reports</i> , 2020 , 10, 13603	4.9	14

229	Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 616564	5.4	2
228	The emotional and social burden of heart failure: integrating physicians, patients and caregivers' perspectives through narrative medicine. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 522	2.3	5
227	New approach to blood pressure control: Triple combination pill. <i>Trends in Cardiovascular Medicine</i> , 2020 , 30, 72-77	6.9	5
226	Prognostic relevance of GRACE risk score in Takotsubo syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 721-728	4.3	10
225	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
224	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
223	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
222	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
221	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
220	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension 2020 , 15, e0237297		
219	Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 399-404	2.9	4
218	Arterial hypertension in cancer: The elephant in the room. <i>International Journal of Cardiology</i> , 2019 , 281, 133-139	3.2	29
217	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019 , 74, 130-136	8.5	9
216	Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?. <i>Internal and Emergency Medicine</i> , 2019 , 14, 903-905	3.7	
215	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	15
214	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. <i>International Journal of Cardiology</i> , 2019 , 291, 105-111	3.2	3
213	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019 , 285, 40-48	3.1	23
212	Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019 , 42, 610-616	1.6	2

211	Tales in Cardiology. <i>European Heart Journal</i> , 2019 , 40, 800-802	9.5	3
210	Molecular and clinical implications of natriuretic peptides in aortic valve stenosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 129, 266-271	5.8	3
209	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , 2019 , 124, 972-974	15.7	3
208	Hypertension in the elderly: which are the blood pressure threshold values?. <i>European Heart Journal Supplements</i> , 2019 , 21, B105-B106	1.5	4
207	Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
206	Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome. <i>Cardiology</i> , 2019 , 142, 232-234	1.6	1
205	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , 2019 , 21, 85	4.7	6
204	Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1863-1871	2.3	3
203	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019 , 286, 127-133	3.2	8
202	Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 771-779	1.9	2
201	Electrocardiographic changes in focal takotsubo syndrome: a case report. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 783-786	1.9	1
200	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 467-473	2.9	2
199	Aspirin in primary prevention: Nothing else matters like hypertension. <i>Journal of Hypertension</i> , 2019 , 37, 2298-2299	1.9	1
198	Reclassification of Hypertensive Outpatients According to New US Guidelines on High Blood Pressure. <i>American Journal of Hypertension</i> , 2019 , 32, 77-87	2.3	13
197	Natriuretic peptides in heart failure: Current achievements and future perspectives. <i>International Journal of Cardiology</i> , 2019 , 281, 186-189	3.2	17
196	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. <i>Journal of Human Hypertension</i> , 2019 , 33, 298-307	2.6	4
195	Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. <i>Advances in Therapy</i> , 2019 , 36, 278-297	4.1	6
194	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019 , 40, 997-1008	9.5	40

193	How to Improve Patients' Adherence to Antihypertensive Therapy: A Simple Solution for a Big Trouble. <i>American Journal of Hypertension</i> , 2019 , 32, 141-142	2.3	
192	Response to letter from Madias regarding our article "Admission heart rate and in-hospital course of patients with Takotsubo syndrome". <i>International Journal of Cardiology</i> , 2019 , 274, 64	3.2	
191	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019 , 40, 383-391	9.5	33
190	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2019 , 59, 1605-1618	11.5	64
189	VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. <i>Hypertension</i> , 2018 , 71, 638-647	8.5	46
188	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 967-973	3.3	6
187	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. <i>Clinical Cardiology</i> , 2018 , 41, 788-796	3.3	5
186	Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 297-305	2.3	27
185	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. <i>Revista Portuguesa De Cardiologia</i> , 2018 , 37, 351.e1-351.e4	1	1
184	Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1999-2010	15.1	114
183	Patient at intermediate cardiovascular risk: statins, yes! - antihypertensive therapy, maybe. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19 Suppl 1, e130-e132	1.9	1
182	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018 , 250, 207-214	3.2	29
181	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66. <i>International Journal of Cardiology</i> , 2018 , 268, 179-186	3.2	32
180	Admission heart rate and in-hospital course of patients with Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2018 , 273, 15-21	3.2	20
179	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018 , 25, 253-259	2.9	3
178	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1238-1246	2.3	14
177	The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	6
176	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698

175	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018 , 271, 125-131	3.2	11
174	Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks". <i>Journal of Clinical Hypertension</i> , 2018 ,	2.3	8
173	Is early and fast blood pressure control important in hypertension management?. <i>International Journal of Cardiology</i> , 2018 , 254, 328-332	3.2	29
172	Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. <i>Journal of Hypertension</i> , 2018 , 36, 1902-1914	1.9	12
171	Measuring Central or Peripheral Blood Pressure Levels? That is the Question in the Modern Clinical Practice of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018 , 25, 415-416	2.9	1
170	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018 , 25, 327-341	2.9	12
169	Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12471	3.3	8
168	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018 , 122, 1924-1931	3	11
167	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. <i>International Journal of Cardiology</i> , 2018 , 268, 27-33	3.2	20
166	Long-Term Outcome of Acute Coronary Syndromes in Young Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 77-84	2.9	9
165	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017 , 241, 50-56	3.2	10
164	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. <i>Nature Reviews Cardiology</i> , 2017 , 14, 560-566	14.8	11
163	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 313-329	2.9	7
162	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA Levels. <i>Diabetes</i> , 2017 , 66, 2472-2482	2.9	105
161	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 331-339	2.9	6
160	Favourable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2017 , 35, 2086-2094	1.9	8
159	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 243-253	2.9	3
158	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 255-263	2.9	3

157	QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. <i>Journal of Cardiology</i> , 2017 , 70, 310-315	3	5
156	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017 , 248, 326-332	3.2	18
155	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. <i>International Journal of Cardiology</i> , 2017 , 248, 342-348	3.2	10
154	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 463-472	2.9	12
153	Personalized medicine-a modern approach for the diagnosis and management of hypertension. <i>Clinical Science</i> , 2017 , 131, 2671-2685	6.5	41
152	An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. <i>Cardiovascular Research</i> , 2017 , 113, 378-388	9.9	109
151	Reduced brain UCP2 expression mediated by microRNA-503 contributes to increased stroke susceptibility in the high-salt fed stroke-prone spontaneously hypertensive rat. <i>Cell Death and Disease</i> , 2017 , 8, e2891	9.8	25
150	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. <i>Clinical Hypertension</i> , 2017 , 23, 10	4.8	3
149	Tortuosity, Recurrent Segments, and Bridging of the Epicardial Coronary Arteries in Patients With the Takotsubo Syndrome. <i>American Journal of Cardiology</i> , 2017 , 119, 243-248	3	16
148	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2017 , 28, 103-108	2.7	14
147	In vitro characterization of mitochondrial function and structure in rat and human cells with a deficiency of the NADH: ubiquinone oxidoreductase Ndufc2 subunit. <i>Human Molecular Genetics</i> , 2017 , 26, 4541-4555	5.6	17
146	Current Situation of Medication Adherence in Hypertension. <i>Frontiers in Pharmacology</i> , 2017 , 8, 100	5.6	116
145	Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. <i>Frontiers in Pharmacology</i> , 2017 , 8, 111	5.6	8
144	Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1690-1699	3.9	13
143	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2016 , 18, 127	4.2	3
142	National Cross-Sectional Survey on Blood Pressure: A Gateway to a Better Appraisal of Hypertension in the Young. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016 , 23, 141-2	2.9	
141	Transfemoral approach with systematic use of FemoSeal closure device compared to transradial approach in primary angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 849-54	2.7	9
140	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. <i>Atherosclerosis</i> , 2016 , 246, 214-20	3.1	17

139	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , 2016 , 29, 509-18	2.3	15
138	A New Electrocardiographic Marker of Sudden Death in Brugada Syndrome: The S-Wave in Lead I. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1427-1440	15.1	99
137	NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. <i>Cardiovascular Revascularization Medicine</i> , 2016 , 17, 162-8	1.6	4
136	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. <i>Heart</i> , 2016 , 102, 602-9	5.1	34
135	Novel Insights Into the Mechanisms Regulating Pro-Atrial Natriuretic Peptide Cleavage in the Heart and Blood Pressure Regulation: Proprotein Convertase Subtilisin/Kexin 6 Is the Corin Activating Enzyme. <i>Circulation Research</i> , 2016 , 118, 196-8	15.7	11
134	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. <i>Clinical Science</i> , 2016 , 130, 57-77	6.5	149
133	Mitochondrial Dysfunction Contributes to Hypertensive Target Organ Damage: Lessons from an Animal Model of Human Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 1067801	6.7	24
132	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	13
131	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	25
130	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016 , 34, 1480-8	1.9	31
129	Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. <i>Data in Brief</i> , 2016 , 7, 1409-12	1.2	5
128	Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. <i>International Journal of Cardiology</i> , 2016 , 221, 881-5	3.2	2
127	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016 , 23, 387-393	2.9	13
126	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 551-6	2.3	36
125	Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 150-8		106
124	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 381-8	2.9	28
123	Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 163-70	4	4
122	mTORC2 regulates cardiac response to stress by inhibiting MST1. <i>Cell Reports</i> , 2015 , 11, 125-36	10.6	84

121	An easy and reproducible parameter for the assessment of the pressure gradient in patients with aortic stenosis disease: A magnetic resonance study. <i>Journal of Cardiology</i> , 2015 , 65, 369-76	3	3
120	Calcium channel blockers and hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015 , 20, 121-30	2.6	20
119	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015 , 36, 817-28	9.5	57
118	Impact of hypertension on global cardiovascular risk stratification: analysis of a large cohort of outpatient population in Italy. <i>Clinical Cardiology</i> , 2015 , 38, 39-47	3.3	5
117	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. <i>Clinical Cardiology</i> , 2015 , 38, 387-94	3.3	15
116	Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 893-899	2.7	40
115	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 656-61	2.7	2
114	Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. <i>Clinical Interventions in Aging</i> , 2015 , 10, 1575-86	4	5
113	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. <i>Internal and Emergency Medicine</i> , 2015 , 10, 943-54	3.7	7
112	In memory of Professor John H. Laragh. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 197	2.9	
111	Cardiovascular prevention: the role of second generation of nutraceuticals. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 155-7	2.9	1
110	A Novel Electrocardiographic T-Wave Measurement (Tp-Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for First-Line Electrocardiographic Evaluation. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 441-9	2.3	12
109	Differential modulation of AMPK/PPAR α /JCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously hypertensive rat strains. <i>Oncotarget</i> , 2015 , 6, 18800-18	3.3	23
108	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 353-63	2.6	8
107	Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 271-9	2.6	10
106	Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. <i>International Journal of Molecular Sciences</i> , 2014 , 16, 823-39	6.3	74
105	ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014 , 21, 137-47	2.9	22
104	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014 , 172, 17-23.2		17

103	Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. <i>Advances in Therapy</i> , 2014 , 31, 561-74	4.1	7
102	Natriuretic peptides in cardiovascular diseases: current use and perspectives. <i>European Heart Journal</i> , 2014 , 35, 419-25	9.5	169
101	An atypical clinical presentation of renovascular hypertension. <i>International Journal of Cardiology</i> , 2014 , 177, e107-10	3.2	1
100	The C2238/ANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells. <i>PLoS ONE</i> , 2014 , 9, e113108	3.7	10
99	New insights into the role of mitochondrial dynamics and autophagy during oxidative stress and aging in the heart. <i>Oxidative Medicine and Cellular Longevity</i> , 2014 , 2014, 210934	6.7	72
98	Natriuretic peptides and cardio-renal disease. <i>International Journal of Cardiology</i> , 2014 , 176, 630-9	3.2	78
97	NOX4 regulates autophagy during energy deprivation. <i>Autophagy</i> , 2014 , 10, 699-701	10.2	39
96	Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients. <i>Hypertension</i> , 2014 , 64, 717-24	8.5	18
95	α-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 1314-9	9.4	4
94	Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. <i>ISRN Cardiology</i> , 2014 , 2014, 652421		4
93	Novel Galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease. <i>Gene</i> , 2014 , 535, 365-9	3.8	13
92	2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013 , 20, 45-52	2.9	47
91	Olmесartan in the treatment of hypertension in elderly patients: a review of the primary evidence. <i>Drugs and Aging</i> , 2013 , 30, 987-98	4.7	9
90	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
89	Plasma renin and cardiovascular risk: what is the evidence for an association?. <i>Cardiology</i> , 2013 , 125, 50-9	1.6	7
88	Clinical management of coronary heart disease in hypertension : practical recommendations from the Italian Society of Hypertension (SIIA). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013 , 20, 129-34	2.9	5
87	Renin-angiotensin system blockers increase risk of angio-oedema. <i>Evidence-Based Medicine</i> , 2013 , 18, e52		
86	Follow-up, study design and outcome parameters. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R96-100	3.1	1

85	Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. <i>Clinical Drug Investigation</i> , 2012 , 32, 649-64	3.2	40
84	Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. <i>Clinical Research in Cardiology</i> , 2012 , 101, 761-6	6.1	14
83	Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012 , 19, 237-44	2.9	17
82	Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. <i>Drugs and Aging</i> , 2012 , 29, 981-92	4.7	10
81	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012 , 19, 129-135	2.9	
80	New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. <i>Integrated Blood Pressure Control</i> , 2012 , 5, 19-25	3.5	9
79	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. <i>Vascular Health and Risk Management</i> , 2012 , 8, 371-80	4.4	14
78	Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 409-12	3	20
77	Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 1061-72	2.5	8
76	Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. <i>Journal of Hypertension</i> , 2012 , 30, 1468-77	1.9	16
75	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. <i>Journal of Hypertension</i> , 2012 , 30, 1056-64	1.9	63
74	Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?. <i>Journal of Hypertension</i> , 2012 , 30, 647-54	1.9	13
73	Global cardiovascular risk management in primary prevention. <i>Current Vascular Pharmacology</i> , 2012 , 10, 709-11	3.3	1
72	Use of aliskiren in a real-life model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. <i>Journal of Hypertension</i> , 2012 , 30, 194-203	1.9	15
71	End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. <i>Drugs</i> , 2011 , 71, 1003-17	12.1	7
70	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2011 , 149, 250-252	3.2	11
69	Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) educational program. <i>Clinical Cardiology</i> , 2011 , 34, 560-6	3.3	10
68	Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. <i>Current Hypertension Reports</i> , 2011 , 13, 318-24	4.7	25

67	An analysis of the management of cardiovascular risk factors in routine clinical practice in Italy: an overview of the main findings of the EFFECTUS study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011 , 18, 19-30	2.9	7
66	Chronic kidney disease in the hypertensive patient: an overview of the I-DEMAND study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011 , 18, 31-6	2.9	2
65	2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011 , 18, 37-40	2.9	5
64	Prevalence of Borderline Values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011 , 18, 43-51	2.9	3
63	Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011 , 18, 93-105	2.9	14
62	Redefining blood pressure targets in high-risk patients?: lessons from coronary endpoints in recent randomized clinical trials. <i>American Journal of Hypertension</i> , 2011 , 24, 1060-8	2.3	11
61	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. <i>American Journal of Hypertension</i> , 2011 , 24, 582-90	2.3	65
60	Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. <i>European Heart Journal</i> , 2011 , 32, 19-22	9.5	31
59	The challenge of polypharmacy in cardiovascular medicine. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 9-17	3.1	46
58	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 811-20	2.5	16
57	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 37-47	2.9	11
56	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 73-102	2.9	9
55	NT-proANP/ANP is a Determinant of Vascular Damage in Humans. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 117-120	2.9	3
54	2009 SIPREC Consensus Document [Executive Summary]. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 237-247	2.9	
53	The cardiovascular continuum refined: A hypothesis. <i>Blood Pressure</i> , 2010 , 19, 273-7	1.7	7
52	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. <i>Journal of Hypertension</i> , 2010 , 28, 156-62	1.9	37
51	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. <i>Journal of Hypertension</i> , 2010 , 28, 251-8	1.9	21
50	Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. <i>Clinical Cardiology</i> , 2010 , 33, 700-7	3.3	25

49	Hypertension as an underlying factor in heart failure with preserved ejection fraction. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 277-83	2.3	15
48	Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. <i>Clinical Drug Investigation</i> , 2009 , 29, 381-91	3.2	39
47	Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. <i>Clinical Drug Investigation</i> , 2009 , 29, 11-25	3.2	69
46	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. <i>Journal of Hypertension</i> , 2009 , 27, 941-6	1.9	27
45	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. <i>Journal of Hypertension</i> , 2009 , 27, S3-11	1.9	26
44	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. <i>Clinical Science</i> , 2009 , 116, 467-77	6.5	106
43	Global Cardiovascular Risk Assessment in Different Clinical Settings. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009 , 16, 55-63	2.9	12
42	Cardiovascular Risk Management in Clinical Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 9-16	2.9	3
41	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 17-22	2.9	1
40	A New Option for Therapeutic Management of Patients with Cardiovascular Disease : A Closer Look at the ONTARGET Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 47-51	2.9	3
39	2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 63-73	2.9	3
38	Cardiovascular risk in hypertension - can we ask for more? : focus on aliskiren. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 255-68	2.9	4
37	Development of heart failure in recent hypertension trials. <i>Journal of Hypertension</i> , 2008 , 26, 1477-86	1.9	80
36	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>Journal of Hypertension</i> , 2007 , 25, 2317-24	1.9	61
35	Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. <i>Journal of Hypertension</i> , 2007 , 25, 2390-7	1.9	11
34	Blood pressure control in Italy: results of recent surveys on hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1491-8	1.9	103
33	Arterial Stiffness and Cognitive Impairment in the Elderly. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 33-37	2.9	5
32	The Role of Arterial Stiffness in Stratifying the Overall Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 89-97	2.9	

31	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 139-144	2.9	
30	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 201-206	2.9	
29	Effects of Olmesartan on Endothelial Function. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 221-227	2.9	1
28	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2007 , 28, 88-136	9.5	889
27	Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. <i>Journal of Nephrology</i> , 2007 , 20 Suppl 12, S12-8	4.8	3
26	Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, S36-43	12.7	31
25	Treatment of High-Risk Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 13-19	2.9	
24	The Apelin/APJ System. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 159-162	2.9	
23	Antihypertensive therapy and cerebrovascular protection. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 498-504	3.5	8
22	Treating Hypertension with Angiotensin II Receptor Blockers. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 9-15	2.9	2
21	A Novel Molecule of the Angiotensin II Receptor Blocker Class. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 79-89	2.9	1
20	Natriuretic Peptides. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 215-223	2.9	1
19	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. <i>Journal of Hypertension</i> , 2005 , 23, 2113-8	1.9	37
18	Angiotensin II-receptor antagonist in the treatment of hypertension. <i>Current Hypertension Reports</i> , 2005 , 7, 287-93	4.7	6
17	Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. <i>Aging Clinical and Experimental Research</i> , 2005 , 17, 46-53	4.8	3
16	Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1151-60	2.5	12
15	Hypertension and heart failure: role of neurohormonal mechanisms. <i>Clinical and Experimental Hypertension</i> , 2004 , 26, 603-10	2.2	7
14	Hypertension therapy: mixing, matching, and meeting targets. <i>Advances in Therapy</i> , 2004 , 21, 107-22	4.1	4

13	Angiotensin II: an amplifier of cardiovascular risk. <i>Current Hypertension Reports</i> , 2004 , 6, 247-8	4.7	5
12	Protocol for an Observational Blood Pressure Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004 , 11, 11-14	2.9	2
11	The REACT Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004 , 11, 61-63	2.9	0
10	Cardiovascular Risk Profile in 14 513 Patients with Essential Hypertension Followed by Italian Specialist Physicians. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004 , 11, 165-173	2.9	5
9	The REassessment of Antihypertensive Chronic Therapy (REACT) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004 , 11, 175-185	2.9	13
8	Beyond hypertension toward guidelines for cardiovascular risk reduction. <i>American Journal of Hypertension</i> , 2004 , 17, 1068-74	2.3	30
7	Is it time to measure microalbuminuria in hypertension?. <i>Journal of Hypertension</i> , 2003 , 21, 1213-20	1.9	35
6	Treatment of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003 , 10, 7-9	2.9	
5	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003 , 10, 11-18	2.9	
4	The New JNC VII and ESH/ISH Hypertension Recommendations. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003 , 10, 65-67	2.9	
3	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003 , 10, 81-86	2.9	5
2	Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. <i>Circulation</i> , 1998 , 98, 2849-54	16.7	53
1	Regulation of aldosterone biosynthesis by adrenal renin is mediated through AT1 receptors in renin transgenic rats. <i>Circulation Research</i> , 1995 , 77, 73-9	15.7	8